Stockscreener 앱 받기
3.13
19.54%
-0.76
시간 외 거래:
3.13
Onkure Therapeutics Inc 주식(OKUR)의 최신 뉴스
OKUR stock touches 52-week low at $3.39 amid market challenges - Investing.com
We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate - simplywall.st
OKUR stock touches 52-week low at $4.43 amid market challenges - Investing.com Australia
OKUR stock touches 52-week low at $4.43 amid market challenges By Investing.com - Investing.com South Africa
Q1 EPS Estimate for OnKure Therapeutics Lowered by Analyst - Defense World
OnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on Thursday - Defense World
H.C. Wainwright cuts OnKure Therapeutics price target to $34 By Investing.com - Investing.com Australia
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies - TipRanks
H.C. Wainwright cuts OnKure Therapeutics price target to $34 - Investing.com India
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025 - TipRanks
Analyzing Organogenesis (NASDAQ:ORGO) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OKUR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia
Onkure discovers new PI3Kα inhibitors - BioWorld Online
What is Lifesci Capital’s Estimate for OKUR FY2025 Earnings? - Defense World
Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects - TipRanks
Will OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely? - Yahoo Finance
OnKure Therapeutics (NASDAQ:OKUR) Given New $30.00 Price Target at Oppenheimer - Defense World
OnKure Therapeutics Reports Progress and Financials - TipRanks
OnKure boosts R&D spending with cancer trial underway - BizWest
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating - Marketscreener.com
OnKure Therapeutics price target lowered to $30 from $35 at Oppenheimer - TipRanks
OnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c) - TipRanks
OnKure Therapeutics, Inc. SEC 10-K Report - TradingView
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
OnKure Therapeutics Inc. (OKUR) reports earnings - Quartz
OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences - GlobeNewswire
OnKure Therapeutics (NASDAQ:OKUR) Trading Down 4.7% – Time to Sell? - Defense World
FY2025 Earnings Estimate for OKUR Issued By Leerink Partnrs - Defense World
Vanguard Group Inc's Strategic Acquisition of OnKure Therapeutics Shares - GuruFocus.com
After A Clear Safety Picture, OnKure Prepares For Pivotal PIKture-01 Data On OKI-219 - RTTNews
Jones Trading Initiates Coverage of OnKure Therapeutics (OKUR) with Buy Recommendation - Nasdaq
Jones Trading sets OnKure stock Buy rating, $32 target - MSN
Jones Trading sets OnKure stock Buy rating, $32 target By Investing.com - Investing.com South Africa
OnKure Therapeutics (NASDAQ:OKUR) Trading Down 3.4% – Here’s Why - Defense World
Reneo Pharmaceuticals stock hits 52-week low at $5.66 By Investing.com - Investing.com Australia
Reneo Pharmaceuticals stock hits 52-week low at $5.66 - Investing.com India
Reneo Pharmaceuticals stock hits 52-week low at $7.64 By Investing.com - Investing.com Australia
Reneo Pharmaceuticals stock hits 52-week low at $7.64 - Investing.com India
OnKure Therapeutics (NASDAQ:OKUR) Trading 4% Higher – Time to Buy? - Defense World
Reneo Pharmaceuticals stock hits 52-week low at $7.91 By Investing.com - Investing.com Nigeria
Reneo Pharmaceuticals stock hits 52-week low at $7.91 - Investing.com India
OKUR Stock Hits 52-Week Low at $10.51 Amid Market Challenges - Investing.com Australia
10.70%
자본화:
|
볼륨(24시간):